Apparent lack of prognostic value of MIB-1 index in anal carcinomas treated by radiotherapy
1998

MIB-1 Index and Anal Carcinomas

Sample size: 55 publication Evidence: low

Author Information

Author(s): AS Allal, L Alonso-Pentzke, S Remadi

Primary Institution: University Hospital of Geneva

Hypothesis

Does the MIB-1 index have prognostic value in anal carcinomas treated with radiotherapy?

Conclusion

The MIB-1 index does not predict the outcome of patients with anal carcinomas treated by radiotherapy with or without chemotherapy.

Supporting Evidence

  • The median MIB-1 index was 53%, which is among the highest reported for cancers of epithelial origin.
  • Patients with high vs low MIB-1 indices had similar outcomes in terms of survival and disease control.
  • No significant association was found between MIB-1 indices and various clinicopathological parameters.

Takeaway

This study looked at whether a specific marker called the MIB-1 index could help predict how well patients with anal cancer would do after treatment, but it turned out it didn't help at all.

Methodology

The study analyzed the MIB-1 index in tissue samples from 55 patients with anal carcinoma treated with radiotherapy, using a modified immunoperoxidase technique.

Potential Biases

Potential sampling bias related to variations in the MIB-1 index throughout the tumor specimen.

Limitations

The study is retrospective and based on a small number of events, which may limit the reliability of the findings.

Participant Demographics

{"median_age":65,"gender_ratio":"15 males to 40 females"}

Statistical Information

P-Value

{"overall_survival":0.7,"locoregional_control":0.5,"disease_free_survival":0.5}

Confidence Interval

{"locoregional_control":"95% CI 60-85%","disease_free_survival":"95% CI 56-82%","overall_survival":"95% CI 54-81%"}

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication